Meropenem Dosing for Pediatric ESBL UTI
For children ≥3 months with ESBL-producing urinary tract infections, administer meropenem 20 mg/kg IV every 8 hours (maximum 1 gram per dose). 1
Age-Based Dosing Algorithm
Infants ≥3 Months and Children
- Standard dose: 20 mg/kg IV every 8 hours
- Maximum dose: 1 gram per dose
- Administration: IV infusion over 15-30 minutes 1
- For children >50 kg: Use adult dosing of 1 gram every 8 hours 1
Infants <3 Months
Dosing is based on gestational age (GA) and postnatal age (PNA):
- GA <32 weeks + PNA <2 weeks: 20 mg/kg every 12 hours
- GA <32 weeks + PNA ≥2 weeks: 20 mg/kg every 8 hours
- GA ≥32 weeks + PNA <2 weeks: 20 mg/kg every 8 hours
- GA ≥32 weeks + PNA ≥2 weeks: 30 mg/kg every 8 hours 1
All doses for infants <3 months should be given as 30-minute IV infusions.
Clinical Context for ESBL UTIs
Meropenem is the carbapenem of choice for pediatric ESBL UTIs based on FDA-approved dosing and extensive safety data 1. While the FDA label specifically addresses complicated intra-abdominal infections in pediatrics, the 20 mg/kg every 8 hours dosing has been validated in clinical practice for serious infections including UTIs 2, 3.
Important Considerations
- All ESBL E. coli isolates remain universally susceptible to carbapenems (ertapenem and meropenem) 4
- The 20 mg/kg dose achieves peak plasma concentrations of approximately 43-49 mcg/mL with urinary excretion rates of 40-45% 2, 3
- Duration: 7-14 days total therapy is recommended for UTIs 5
- Oral step-down: Consider transitioning to oral antibiotics (if susceptible) once clinically stable to reduce catheter days and complications 6
Renal Impairment
No pediatric dosing adjustments are established for renal impairment—use with caution and consider therapeutic drug monitoring if available 1.
Common Pitfall
Do not use the 40 mg/kg dose (reserved for meningitis) for UTIs—this is excessive and increases seizure risk without added benefit for urinary infections 1.